Table 1.

Baseline Levels and Change Over Time by Treatment Group in Selected Discovery Proteins^¶.

Biomarker†	Baseline level Atorvastatin (N=17)	Change in level Atorvastatin	Baseline level Placebo (N=20)	Change in Level Placebo	t-statistic for treatment effect	P value for treatment effect
TFPI	379.91±52.51	−57.25±16.13	387.43±69.89	25.40± 21.34	−3.00	0.004
CCL24	48.60±40.67	−5.77±3.01	62.03±39.80	10.14±4.39	−2.88	0.005
NT-proBNP	1.41±0.51	0.52±0.24	2.27±2.52	−0.62±0.31	2.83	0.006
MBL2	10.32±1.25	−0.36±0.16	11.17±1.16	0.17±0.13	−2.60	0.01
LTBR	6.97±3.08	−0.47±0.40	7.61±2.37	0.64±0.35	−2.09	0.046
PCOLCE	6.28±0.56	0.55±0.10	6.78±1.51	−0.19±0.34	1.95	0.048
TR	18.28±14.72	−4.50±2.99	16.16±7.91	2.33±1.47	−2.14	0.052
SELE	12.92±7.88	−1.56±1.11	11.14±5.10	1.00±0.76	−1.95	0.07
TNF-R1	60.45±27.97	−5.18±4.75	58.04±19.11	5.44±2.90	−1.97	0.07
CCL16	108.91±58.26	−8.51±6.65	120.92±63.94	7.00±5.44	−1.82	0.08
CHIT1	57.03±37.52	−1.97±4.63	48.47±35.12	7.31±2.20	−1.90	0.08
RETN	82.63±45.87	−13.24±9.90	75.23±23.07	7.95±6.43	−1.85	0.08

^¶­Results for baseline are Mean ± SD and for change results are Mean ± SEM

^†For full list of abbreviations, see Supplemental Tables 1 and 2.